Head & Neck Cancer Therapeutics Market: Top 3 Treatment Options Characterized as a group of cancers of the mouth, nose, throat, or sinuses, head and neck cancer accounts for around 4% of all cancers in the United States . Moreover, an estimated 66,920 people are expected to be diagnosed with the condition in 2023. Although eliminating the malignancy is the primary goal of head and neck cancer treatment and therapeutics, preserving the function of the nearby organs, nerves, and tissues is also crucial. As per Inkwood Research, the global head & neck cancer therapeutics market is projected to grow with a CAGR of 8.60% between 2023 to 2032, reaching a revenue share of $3041.91 million by 2032. The management of head and neck cancers involves a comprehensive approach, taking into account several crucial factors, including the cancer type, stage, the patient’s overall health, and individual preferences. Besides, the pivotal aspect of patient care in head and neck cancers is the collaboration of a multidisciplinary team of head and neck cancer specialists, ensuring that each patient receives personalized and well-coordinated treatment. In this blog, we explore the top 3 treatment modalities available for head and neck cancer as well as their associated market developments –
Chemotherapy - Chemotherapy involves the use of drugs to target and destroy cancer cells, typically by inhibiting their growth, division, and ability to reproduce. The treatment typically follows a specific regimen, with a predetermined number of cycles administered over a set period. Although side effects of chemotherapy vary across patients and depend on the dosage administered, some complications include fatigue, nausea and vomiting, hair loss, increased susceptibility to infections, reduced appetite, and diarrhea. However, these reactions are often temporary and tend to lessen following the completion of treatment. o o
Market Observation – According to our analysis, the chemotherapy segment, under the treatment type category is set to record a CAGR of 8.70% between 2023 to 2032. Chemotherapy Product Developments – Eli Lilly and Co (United States) – The antifolate chemotherapeutic medication Alimta is used to treat malignant pleural mesothelioma and nonsmall cell lung cancer (NSCLC). Amgen Inc (United States) – Neulasta is used to lower the risk of infection in chemotherapy patients and contains the active component pegfilgrastim. It helps promote the production of neutrophils, a type of white blood cell, in the bone marrow. Sanofi (France) – Head and neck cancers are among the major malignancies that can be treated with the chemotherapeutic medication Taxotere.
Immunotherapy – Immunotherapy utilizes the body’s natural defenses to fight cancer by improving the ability of the patient’s immune system to attack cancer cells. Presently, the immunotherapy drugs approved by the United States Food and Drug Administration (FDA) for the treatment of metastatic or recurrent head and neck squamous cell carcinoma include: